Mkule

Mkule is a preclinical-stage biotechnology company based in Ann Arbor, Michigan, focused on the discovery and development of innovative small-molecule protein degraders. Leveraging technology licensed from the University of Michigan, the company targets "undruggable" proteins involved in cancer and other serious diseases. Their platform utilizes Proteolysis-Targeting Chimera (PROTAC) technology to selectively induce the degradation of disease-causing proteins. Mkule's lead programs focus on high-value targets such as STAT3, aiming to provide new therapeutic options for patients with solid tumors and hematologic malignancies.